The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Innate Pharma
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Aduro Biotech; Alphamab; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; Compugen; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Mavu Pharmaceutical; Merck; Newlink Genetics; Novartis; Reflexion Medical; Spring Bank; Syndax; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics; WntRx Pharmaceuticals
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Merck; Novartis; Reflexion Medical
 
Josep Tabernero
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; Symphogen; Taiho Pharmaceutical
 
Anthony Joshua
No Relationships to Disclose
 
Jayesh Desai
Consulting or Advisory Role - Amgen; BeiGene; Bionomics; Eisai; Lilly; Novartis
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Andrea I. Varga
Consulting or Advisory Role - Clovis Oncology
 
Victor Moreno
No Relationships to Disclose
 
Carlos A. Gomez-Roca
No Relationships to Disclose
 
Ben Markman
No Relationships to Disclose
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Dompè; Ignyta; Novartis; Pfizer; SERVIER; Tiziana Life Sciences
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar; Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Sandip Pravin Patel
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Compugen; Lilly; Nektar; Novartis
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Pfizer (Inst); Roche/Genentech (Inst); Xcovery (Inst)
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Lillian L. Siu
Leadership - Agios (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck; MorphoSys; Roche; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Giuseppe Curigliano
Consulting or Advisory Role - Pfizer; Roche/Genentech
Speakers' Bureau - Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Zhaohui Liu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Yuko Ishii
Employment - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Millennium; Takeda
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb
Other Relationship - Agios
 
Megan Wind-Rotolo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Other Relationship - Huntsworth Health (I)
 
Paul Andrew Basciano
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Alex Azrilevich
Employment - Bristol-Myers Squibb
Leadership - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Karen A. Gelmon
Consulting or Advisory Role - AstraZeneca; Merck; Novartis; Pfizer
Expert Testimony - Genentech